Physician profile
Scott Podnos
NPI 1053421446
$3,505.60
in general payments reported to CMS, 2019-2025
33 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $36.06 · 2021: $133 · 2022: $350 · 2023: $651 · 2024: $750 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.41 | 2019-2025 | |
| Organogenesis INC. | $277.73 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Genzyme Corporation | $268.91 | 2024-2025 | |
| Amgen INC. | $249.86 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $214.72 | 2022-2025 | Dupixent, Libtayo |
| Celgene Corporation | $150.68 | 2019 | |
| Janssen Biotech, INC. | $144.63 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $133.14 | 2021-2025 | Ilumya |
| Allergan, INC. | $123.49 | 2019 | |
| Prugen, INC. Pharmaceuticals | $105.78 | 2019 | |
| Janssen Scientific Affairs, LLC | $101.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.42 | 2019-2024 | |
| Smith+Nephew, INC. | $62.70 | 2022-2023 | Grafix Pl |
| Biofrontera INC. | $62.14 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Kerecis Limited | $62.05 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $61.22 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $60.51 | 2021-2023 | Taltz |
| Ucb, INC. | $56.18 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.25 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $36.66 | 2021-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $27.78 | 2019-2022 | |
| Dermira, INC. | $26.45 | 2019 | |
| Fidia Pharma USA INC. | $25.32 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.13 | 2022 | |
| Kyowa Kirin, INC. | $21.74 | 2024 | Poteligeo |
| Pfizer INC. | $21.15 | 2021 | |
| Nabriva Therapeutics, Plc | $21.07 | 2022 | |
| Blueprint Medicines Corporation | $19.57 | 2023 | |
| Acera Surgical, INC. | $16.75 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.10 | 2023 | Nuzyra |
| Lnhc, INC | $13.97 | 2025 | Zelsuvmi |
| Merz North America, INC. | $13.96 | 2025 | |
| Strata Skin Sciences, INC. | $13.65 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Podnos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.